

# Table of Contents

<b>General Introduction.</b> J. M. VAN ROSSUM . . . . .	1
---	---

## CHAPTER 1

### **Physicochemical Fundamentals and Thermodynamics of the Membrane Transport of Drugs.** W. SCHELER and J. BLANCK with the assistance of E. KAHRIG, D. KIRSTEIN, K.-U. MÖRITZ and G. RAHMEL. With 11 Figures

I. Introduction . . . . .	3
II. Systems and Membrane Types . . . . .	3
A. Homogenous System . . . . .	3
B. Heterogeneous Continuous System . . . . .	4
C. Heterogeneous Discontinuous System . . . . .	4
D. Membrane Types . . . . .	4
1. Liquid-Phase Membranes . . . . .	4
2. Pore Membranes . . . . .	4
a) Narrow-Pore Membranes . . . . .	5
b) Coarse-Pore Membranes . . . . .	5
c) Charged Porous Membranes . . . . .	5
3. Composed Membranes . . . . .	6
a) Composed Pore Membranes . . . . .	6
b) Composed Liquid Phase-Pore Membranes . . . . .	6
4. Biological Membranes . . . . .	7
a) Membranes with Passive Carrier Transport . . . . .	8
b) Membranes with Active Transport . . . . .	8
III. Classification of Membrane Transport . . . . .	8
A. Diffusion Across Membranes . . . . .	9
1. Driving Forces . . . . .	9
2. Mechanism and Kinetics . . . . .	10
3. Specificity . . . . .	11
4. Inhibition Characteristics . . . . .	12
B. Facilitated Diffusion . . . . .	13
1. Mechanism . . . . .	13
2. Driving Force . . . . .	14
3. Counter-Transport . . . . .	14
4. Kinetics . . . . .	14

5. Specificity . . . . .	15
6. Competitive Inhibition . . . . .	15
C. Active Transport . . . . .	15
D. Pinocytosis . . . . .	17
1. Mechanism . . . . .	17
2. Specificity . . . . .	18
3. Inhibition . . . . .	18
IV. Kinetics and Thermodynamics of Membrane Transport . . . . .	18
A. Conventional Equations . . . . .	18
B. Introductory Remarks on the Thermodynamics of Irreversible Processes . . . . .	19
C. Passive Transport of Nonelectrolytes . . . . .	20
1. Flux Equations . . . . .	20
2. Significance of the Phenomenologic Coefficients . . . . .	23
a) Ideal Semipermeable Membrane . . . . .	23
b) Coarse Porous Membrane . . . . .	24
c) Reflection Coefficient . . . . .	24
d) Permeability Coefficient . . . . .	25
3. Coupling of Fluxes . . . . .	26
4. Interpretation of Membrane Transport by Means of Frictional Coefficients . . . . .	27
a) General Equations . . . . .	27
b) Connections Between Frictional and Phenomenologic Coefficients . . . . .	28
c) Physical Significance of the Coefficients . . . . .	29
D. Passive Transport of Electrolytes Across Charged Membranes . . . . .	30
1. General Relations . . . . .	30
2. Introduction of Frictional Coefficients . . . . .	31
3. Permeability and Reflection Coefficients of 1—1-Valent Salts . . . . .	32
4. Permeability and Reflection Coefficients of 1—2- and 2—1-Valent Salts . . . . .	33
E. Passive Carrier Transport . . . . .	34
Kinetic Analysis and Flux Equations . . . . .	34
a) Basic Equations . . . . .	34
b) Limiting Cases . . . . .	37
c) Counter-Transport and Competitive Exchange Diffusion . . . . .	37
F. Active Transport . . . . .	39
1. Kinetic Analysis and Conventional Flux Equations . . . . .	39
2. Phenomenologic Treatment. Flux Equations . . . . .	41
G. Remarks on Nonlinear Thermodynamic Approach to Membrane Transport . . . . .	43
1. Introduction . . . . .	43
2. Examples and Models . . . . .	44
Appendix. Glossary of Symbols . . . . .	48
References . . . . .	50

## CHAPTER 2

**Pharmacokinetics. Kinetic Aspects of Absorption, Distribution, and Elimination of Drugs. E. KRÜGER-THIEMER. With 21 Figures**

I. Introduction . . . . .	63
A. Basic Definitions . . . . .	63
B. Historical Outline . . . . .	67
II. Pharmacokinetic Models . . . . .	68
A. Choice of Models . . . . .	68
B. Critique of Models . . . . .	71
III. Models for Single-Dose Administration . . . . .	71
A. Intra- and Extravascular Administration . . . . .	72
B. Elimination. . . . .	75
1. Biotransformation . . . . .	77
2. Renal Excretion . . . . .	80
3. Extrarenal Excretion . . . . .	82
C. Distribution . . . . .	83
Protein Binding Models . . . . .	83
D. Absorption . . . . .	92
1. Absorption from Parenteral Sites . . . . .	93
2. Absorption from Enteral Sites . . . . .	94
3. Transport Through the Gastrointestinal Tract . . . . .	95
4. Absorption from Gastrointestinal Tract . . . . .	98
5. First-Order Absorption Kinetics with Zero-Time Shift . . . . .	98
6. Nonfirst-Order Models of Absorption . . . . .	99
E. Multicompartment Kinetics. . . . .	100
1. The Two Compartment Model . . . . .	101
2. The Slope of the Log Concentration-Time Curve . . . . .	104
3. A Three Compartment Model . . . . .	104
IV. Multiple Dose Administration . . . . .	106
A. The Therapeutic Purpose . . . . .	106
1. Intravascular Administration of Multiple Doses . . . . .	107
2. Continuous Intravenous Infusion . . . . .	109
3. Extravascular Administration of Multiple Dose Therapy . . . . .	109
4. Drug Accumulation and the Desired Plateau Effect . . . . .	110
B. Dosage Regimens . . . . .	110
1. Empirical Rules for Dosage Regimens . . . . .	110
2. Theory of Dosage Regimens . . . . .	111
3. Theory of Dosage Regimens: The Average Concentration in the Dosage Interval . . . . .	113
4. Dosage Regimens for Rapidly Absorbed Drugs . . . . .	114
5. Dosage Regimens for Slowly Absorbed Drugs . . . . .	115
V. Conclusion . . . . .	117
References . . . . .	117

## CHAPTER 3

**Pharmacokinetics of Biotransformation.** J. M. VAN ROSSUM, C. A. M. VAN GINNEKEN, P. Th. HENDERSON, H. C. J. KETELAARS, and T. B. VREE. With 21 Figures

I. Introduction . . . . .	125
A. Elimination of Drugs by a Clearance Process . . . . .	125
B. Flow-Limited Elimination of Drugs . . . . .	127
C. Supply-Limited Elimination of Drugs . . . . .	128
D. Capacity-Limited Elimination of Drugs . . . . .	129
E. The Relationship Between the Metabolic Enzyme Activity and the Metabolic Clearance . . . . .	130
F. The Plasma Decay Curve as a Result of Metabolic Clearance . . . . .	132
G. Calculation of Enzymatic Constants from the Plasma Decay Curve . . . . .	135
H. Simultaneous Supply-Limited and Capacity-Limited Elimination of Drugs . . . . .	137
I. Dissociation Constants Obtained from Microsomal Enzymes . . . . .	140
J. Inhibition of Drug Metabolism by Other Drugs . . . . .	143
K. Induction of Microsomal Enzymes and the Liver Clearance . . . . .	145
L. The Liver Clearance Under Pathologic Conditions . . . . .	146
M. Drug-Dependent Destruction of Metabolic Clearance Processes . . . . .	147
N. Elimination of Parent Drug and its Metabolite . . . . .	148
O. Saturation Kinetics of Metabolite Formation and Capacity-Limited Elimination . . . . .	149
P. Multicompartment Kinetics and Capacity-Limited Elimination . . . . .	151
Q. Oral Administration and Capacity-Limited Elimination . . . . .	153
R. Oral Administration and Capacity-Limited Elimination in the Liver . . . . .	155
S. The Accumulation Plateau Following Repetitive Dosing of a Drug . . . . .	158
T. The Accumulation Plateau and Capacity-Limited Elimination . . . . .	158
U. The Accumulation Plateau and Capacity-Limited Elimination in the Liver Compartment . . . . .	161
V. The Renal Excretion Rate in Case of Capacity-Limited Elimination . . . . .	162
W. Metabolite Concentrations Following Chronic Medication . . . . .	163
X. Bioavailability and Capacity-Limited Elimination . . . . .	164
II. Conclusion . . . . .	165
References . . . . .	165

## CHAPTER 4

**General Theory of Drug-Receptor Interactions.** Drug-Receptor Interaction Models. Calculation of Drug Parameters. F. G. VAN DEN BRINK. With 28 Figures

I. Introduction . . . . .	169
A. The Utility of Theoretical Mathematical Models in Molecular Pharmacology . . . . .	169
B. The Affinity Between Drug Molecules and Receptors; the Concepts Drug Activity and Receptor . . . . .	170
C. Intrinsic Activity; the Concepts Agonism, Competitive Antagonism, and Dualism . . . . .	172

II. Drugs, Receptors and Effects . . . . .	174
A. Different Types of Antagonism . . . . .	174
1. Chemical Antagonism . . . . .	174
2. Competitive Antagonism . . . . .	175
3. Noncompetitive Antagonism . . . . .	175
a) Metaffinoid Antagonism . . . . .	175
b) Metactoid Antagonism . . . . .	175
4. Functional Antagonism . . . . .	176
5. Physical Antagonism. . . . .	176
B. Classification of Drugs in Families . . . . .	177
C. From Drug Administration to Effect; Drug-Receptor Interaction Models; Experiments on Isolated Organs . . . . .	178
III. Agonistic Interaction . . . . .	181
A. The Model of Agonism . . . . .	181
B. Intrinsic Activity in the Agonistic Formula . . . . .	184
C. Theoretical Concentration-Effect Curves. Sets of Curves Characterized by Parallel Shifting or by a Change in Slope . . . . .	188
D. Discussion of the Presuppositions in the Agonistic Model . . . . .	191
IV. Competitive Interaction . . . . .	192
A. The Model of Competitive Interaction . . . . .	192
B. Implications of the Model of Competitive Interaction . . . . .	194
V. Metactoid Interaction . . . . .	200
A. The Model of Metactoid Interaction . . . . .	200
B. Implications of the Model of Metactoid Interaction; the Concept Receptor Reserve . . . . .	204
VI. Metaffinoid Interaction . . . . .	207
A. The Model of Metaffinoid Interaction . . . . .	207
B. Metaffinoid Interaction. Implications of Equation 55 . . . . .	212
C. An Alternative Model for Metaffinoid Interaction . . . . .	214
D. A More Generalized Metaffinoid Model . . . . .	216
VII. Functional Interaction . . . . .	222
A. The Model of Functional Interaction . . . . .	222
1. The Original Model of Functional Interaction . . . . .	222
2. A New Model of Functional Interaction . . . . .	223
B. Implications of the New Model of Functional Interaction . . . . .	231
VIII. Plural Affinities . . . . .	234
IX. Numerical Expressions of Intrinsic Activity and Affinity . . . . .	237
A. Calculation of $\alpha^E$ and $pD_2$ . . . . .	238
B. Calculation of $pK_A^S$ and $\alpha^S$ . . . . .	239
C. Calculation of $pA_2$ -values . . . . .	243
D. Calculation of $\beta'^E$ and $pD_2'$ . . . . .	244
E. Affinity and Intrinsic Activity Values for Functional Antagonists . . . . .	247
F. $pA_2$ and $pD_2'$ of a Dual (Competitive and Metactoid) Antagonist . . . . .	247
G. Conclusion . . . . .	249
References . . . . .	249

## CHAPTER 5

**A Critical Survey of Receptor Theories of Drug Action.** D. MACKAY. With 7 Figures

I. Introduction . . . . .	255
II. The Mathematics of Drug-Receptor Interactions . . . . .	257
A. Interaction of One Drug with One Type of Receptor . . . . .	257
1. The Drug-Receptor Reaction . . . . .	257
2. Onset of Receptor Occupation . . . . .	258
3. Offset of Receptor Occupation . . . . .	259
B. Interaction of Two Drugs with the Same Receptors . . . . .	260
1. Competitive Interactions . . . . .	260
2. Pseudo-Irreversible Interactions . . . . .	260
3. Facilitated Displacement . . . . .	261
4. Specific Noncompetitive Interaction . . . . .	261
C. Application of Equations for Receptor Occupation to Macroscopic Tissues . . . . .	262
D. Drug-Receptor Interactions and the Response . . . . .	262
III. Occupation Theories of Drug Action . . . . .	263
A. The Direct Occupation Theory . . . . .	263
1. Clark's Original Theory . . . . .	264
2. Application of the Null Method to Studies of Drug Antagonism . . . . .	264
3. Intrinsic Activity, Efficacy, and the Pharmacologic Stimulus . . . . .	266
a) Intrinsic Activity . . . . .	267
b) Efficacy and the Pharmacologic Stimulus . . . . .	268
4. <i>Intrinsic Efficacy</i> . . . . .	270
5. General Application of the Null Method to the Analysis of Dose- Response Curves . . . . .	271
6. Estimation of Affinity Constants and Intrinsic Efficacies of Agonists . . . . .	272
7. A Discussion of the Direct Occupation Theory of Drug Action . . . . .	274
8. The Equilibrium Assumption . . . . .	276
9. Variation of the Response with Time . . . . .	277
10. A Negative Feedback Model . . . . .	280
11. The Null Method and the Negative Feedback Model . . . . .	284
B. Agonists as Activators of Enzyme Systems . . . . .	285
1. The Conformational Perturbation Theory of Drug Action . . . . .	285
2. The Dynamic-Receptor Hypothesis . . . . .	287
3. Application of the Null Method of the Dynamic-Receptor Hypothesis . . . . .	289
4. Nondynamic Receptors . . . . .	291
5. Comparison of Direct Occupation Theory and Latent-Enzyme Activation Hypotheses . . . . .	292
C. The Flux-Carrier Hypothesis and Intracellular Uptake of Drugs . . . . .	295
1. The Flux-Carrier Hypothesis . . . . .	295
2. Discussion of the Flux-Carrier Model . . . . .	296
3. The Actions of Drugs on Depolarised Tissues, and Possible Intra- cellular Effects of Agonists . . . . .	298

D. The Allosteric Two-State Model . . . . .	299
1. Basis of the Model . . . . .	299
2. Application of the Null Method to the Allosteric Two-State Model, and Comparison of the Results with those Obtained on the Basis of the Direct Occupation Theory. . . . .	301
IV. The Rate Theory of Drug Action . . . . .	303
A. Agonist Action and the Rate Theory . . . . .	303
1. The Kinetics of the Response . . . . .	303
2. Specific Desensitisation . . . . .	307
B. Antagonists and the Rate Theory . . . . .	307
C. Discussion . . . . .	308
V. A General Discussion of the Various Receptor Models . . . . .	311
VI. A General Discussion of the Possible Uses of Receptor Models . . . . .	312
Appendix. Glossary of Symbols . . . . .	314
References . . . . .	316

## CHAPTER 6

**Drug-Receptor Inactivation: A New Kinetic Model.** R. E. GOSSELIN. With 8 Figures

I. Introduction . . . . .	323
II. Energetics of Receptor Activity . . . . .	323
III. Models in Which Trigger Energy is Generated . . . . .	324
IV. Models Involving Irreversible Alterations of Agonist or Receptor . . . . .	326
V. A Receptor Inactivation Theory . . . . .	328
VI. Stationary State Behavior with Single Agonists . . . . .	330
VII. Transient State Behavior with Single Agonists . . . . .	333
VIII. Stationary State Behavior with Agonist-Antagonist Mixtures . . . . .	339
IX. Transient State Behavior with Agonist-Antagonist Mixtures . . . . .	340
X. General Discussion . . . . .	342
XI. Summary . . . . .	344
Addendum A . . . . .	345
Addendum B . . . . .	345
Appendices: Glossary—Generalized Rate Equations for the Receptor In- activation Model—"On" Effect—"Off" Effect—Analysis of Oscillations— Receptor Interactions with Agonist-Antagonist Mixtures . . . . .	346
References. . . . .	354

## CHAPTER 7

**Kinetics of Drug-Receptor Interaction.** C. A. M. VAN GINNEKEN. With 6 Figures

I. Introduction . . . . .	357
A. Drug-Receptor Interactions and Pharmacologic Effect . . . . .	357
B. The Receptor . . . . .	359
II. Diffusion of Drug to Receptor . . . . .	361
A. Free Diffusion of Drug . . . . .	361
B. Effect of Intermolecular Forces on Diffusion . . . . .	362

III. Intermolecular Forces in Drug-Receptor Reactions . . . . .	365
IV. Kinetics of Drug-Receptor Association and Dissociation . . . . .	368
V. Possibilities for Measuring Rate Constants in Drug-Receptor Interaction	371
VI. Conformational Changes in the Drug-Receptor Complex . . . . .	378
VII. Kinetics of Drug-Receptor Interaction, Including Conformational Changes . . . . .	381
A. Conformational Changes that are Fast in Comparison with Association and Dissociation . . . . .	381
B. Conformational Changes that are Slow in Comparison with Association and Dissociation . . . . .	382
C. Conformational Changes and Irreversible Antagonists . . . . .	384
VIII. Some Other Notions in Molecular Pharmacology . . . . .	386
A. Desensitization and Fade . . . . .	386
B. Receptor Reserve . . . . .	388
C. Homogeneity of Receptor Preparations . . . . .	388
D. Allosteric Models . . . . .	389
IX. Activation Parameters . . . . .	389
A. Arrhenius' Equation and Transition-State Theory . . . . .	389
B. Energetics of Drug-Receptor Interaction . . . . .	392
Appendix . . . . .	397
References . . . . .	407
<b>Conclusion.</b> J.M.VAN ROSSUM. With 3 Figures . . . . .	413
<b>Author Index</b> . . . . .	419
<b>Subject Index</b> . . . . .	433